Amicus Therapeutics is the Most Prominent Biopharmaceutical Companies in the United States

Amicus Therapeutics is one of the leading biopharmaceutical companies in the United States. The company is at the forefront of developing medication to treat rare and orphan diseases. Rare and orphan diseases are not common, and they affect less than 200, 000 people in the United States. Due to the rare nature of these conditions, funding to investigate causes and therapies tend to be limited. There are over 7000 recognized diseases worldwide, and over 350 million people are considered to be victims.

 

Amicus Therapeutics is among the few companies that have been able to bring together scientists and resources to find cures to some of these diseases. The company partners with different organizations to facilitate research to find therapies for these rare diseases (https://seekingalpha.com/article/4073303-amicus-therapeutics-small-biotech-seems-big-mo). Amicus Therapeutics has a robust development pipeline to treat a range of human genetic diseases. Its main product is Migalastat, specially made to treat Fabry disease through genetic diagnosis. The drug which trades under the name, Galafold, has been one of the successful products of the company.

 

Amicus Therapeutics has unique platform technologies and medicines that have proved to be very efficient. The concern to help communities has seen some charitable organization fund the company to advance and extend their research on other rare and orphan diseases. There are only a few companies who have the right technology and human resource to venture into this field. For the last few years, the company has been able to offer jaw-dropping returns that have surprised many in the field. The recent approval to sell Galafold to the EU countries is a positive sign of possible expansion of the company. This has also led to increased credibility and reputation of the Amicus Therapeutics.

 

The company is located in Cranbury, New Jersey, and the current chief executive officer is John F. Crowley. John has been in this position since 2005 after succeeding Donald Hayden. His performance has been exemplary, and he helped the company to be listed in 2007 under the NASQAD trading FOLD (google finance). Amicus Therapeutics issued shares successfully to raise capital to advance its research and commercialization programs. The CEO launched another research facility in San Diego with the aim of increasing and facilitating efficiency.